ATRS [NASD]
Antares Pharma, Inc.
Index- P/E21.09 EPS (ttm)0.27 Insider Own2.30% Shs Outstand170.06M Perf Week0.36%
Market Cap953.37M Forward P/E25.64 EPS next Y0.22 Insider Trans0.00% Shs Float167.27M Perf Month0.36%
Income46.30M PEG- EPS next Q0.01 Inst Own55.30% Short Float4.35% Perf Quarter62.03%
Sales184.00M P/S5.18 EPS this Y-19.80% Inst Trans6.07% Short Ratio1.51 Perf Half Y58.36%
Book/sh1.03 P/B5.43 EPS next Y172.50% ROA20.50% Target Price5.95 Perf Year37.01%
Cash/sh0.39 P/C14.21 EPS next 5Y- ROE32.20% 52W Range3.11 - 5.59 Perf YTD56.58%
Dividend- P/FCF31.78 EPS past 5Y29.80% ROI5.80% 52W High0.00% Beta1.12
Dividend %- Quick Ratio2.80 Sales past 5Y28.60% Gross Margin62.90% 52W Low79.74% ATR0.02
Employees201 Current Ratio3.00 Sales Q/Q10.40% Oper. Margin14.90% RSI (14)78.67 Volatility0.22% 0.29%
OptionableYes Debt/Eq0.11 EPS Q/Q-37.40% Profit Margin25.20% Rel Volume0.57 Prev Close5.59
ShortableYes LT Debt/Eq0.10 EarningsMar 03 BMO Payout0.00% Avg Volume4.82M Price5.59
Recom2.80 SMA200.34% SMA5015.76% SMA20043.30% Volume2,707,496 Change0.00%
Jul-16-21Initiated Truist Buy $7
Oct-23-17Reiterated H.C. Wainwright Buy $5 → $3.50
Jun-23-17Initiated H.C. Wainwright Buy $5
Apr-21-17Initiated Raymond James Strong Buy
May-28-15Initiated Jefferies Buy $5
May-18-15Initiated Piper Jaffray Overweight $3.50
Aug-08-13Reiterated Ladenburg Thalmann Buy $5 → $5.75
Jun-21-13Resumed Oppenheimer Outperform $6
May-19-22 09:35AM  
May-12-22 08:00AM  
May-10-22 11:30AM  
May-06-22 05:30PM  
Apr-26-22 01:20PM  
Apr-20-22 09:17AM  
Apr-14-22 10:06AM  
06:26AM  
Apr-13-22 04:44PM  
02:09PM  
11:42AM  
09:12AM  
08:47AM  
08:45AM  
08:33AM  
07:43AM  
06:44AM  
06:21AM  
06:12AM  
06:00AM  
03:52AM  
Mar-29-22 02:29PM  
02:02PM  
07:00AM  
Mar-11-22 04:26AM  
Mar-03-22 08:15AM  
07:00AM  
Feb-28-22 05:25PM  
08:30AM  
Feb-18-22 04:29AM  
Feb-17-22 08:30AM  
Feb-15-22 07:45AM  
Feb-03-22 08:00AM  
Jan-28-22 05:38PM  
Jan-18-22 12:39PM  
07:30AM  
Jan-13-22 04:46AM  
Jan-12-22 08:30AM  
Jan-11-22 07:30AM  
Dec-17-21 07:53AM  
Dec-15-21 05:58PM  
Dec-08-21 04:57AM  
Nov-22-21 08:00AM  
Nov-11-21 10:00AM  
Nov-10-21 08:30AM  
Nov-08-21 08:18AM  
Nov-04-21 08:35AM  
07:00AM  
Oct-28-21 03:05PM  
08:00AM  
Oct-27-21 06:52AM  
Oct-25-21 08:30AM  
Oct-21-21 08:30AM  
Oct-18-21 12:15PM  
07:00AM  
Sep-30-21 09:00AM  
Sep-21-21 06:29AM  
Sep-08-21 08:30AM  
Aug-27-21 10:15AM  
Aug-16-21 06:17AM  
Aug-05-21 07:00AM  
Jul-29-21 05:54PM  
03:05PM  
Jul-28-21 08:30AM  
Jul-22-21 08:30AM  
Jul-11-21 03:29AM  
Jul-07-21 08:30AM  
Jun-28-21 08:30AM  
Jun-22-21 09:00AM  
Jun-15-21 08:30AM  
Jun-05-21 03:19AM  
Jun-01-21 01:38AM  
May-26-21 08:30AM  
May-06-21 09:25AM  
07:15AM  
07:00AM  
06:45AM  
May-03-21 08:30AM  
Apr-29-21 05:03PM  
Apr-28-21 08:30AM  
Apr-27-21 08:30AM  
Apr-26-21 08:30AM  
01:57AM  
Mar-27-21 03:56AM  
Mar-02-21 08:25AM  
07:22AM  
07:00AM  
06:30AM  
Mar-01-21 10:14AM  
Feb-24-21 11:51PM  
04:30PM  
Feb-23-21 08:30AM  
Feb-17-21 08:30AM  
Jan-26-21 12:02AM  
Jan-11-21 08:00AM  
Dec-27-20 01:12AM  
Dec-16-20 11:36AM  
Nov-30-20 11:48PM  
Nov-23-20 04:05PM  
Nov-10-20 04:30PM  
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GUETH ANTONDirectorJul 08Sale4.29100,000429,000467,577Jul 09 05:08 PM